title: Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.
abstract: Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health Canada as an adjunctive therapy in adults with partial-onset seizures (POS). In humans and in relevant animal laboratory species, ESL undergoes extensive first pass hydrolysis to its major active metabolite eslicarbazepine that represents ∼95% of circulating active moieties. ESL and eslicarbazepine showed anticonvulsant activity in animal models. ESL may not only suppress seizure activity but may also inhibit the generation of a hyperexcitable network. Data reviewed here suggest that ESL and eslicarbazepine demonstrated the following in animal models: (1) the selectivity of interaction with the inactive state of the voltage-gated sodium channel (VGSC), (2) reduction in VGSC availability through enhancement of slow inactivation, instead of alteration of fast inactivation of VGSC, (3) the failure to cause a paradoxical upregulation of persistent Na(+) current (I NaP), and (4) the reduction in firing frequencies of excitatory neurons in dissociated hippocampal cells from patients with epilepsy who were pharmacoresistant to carbamazepine (CBZ). In addition, eslicarbazepine effectively inhibited high- and low-affinity hCaV3.2 inward currents with greater affinity than CBZ. These preclinical findings may suggest the potential for antiepileptogenic effects; furthermore, the lack of effect upon KV7.2 outward currents may translate into a reduced potential for eslicarbazepine to facilitate repetitive firing.
authors.affiliation: BIAL - Portela & Cª, S.A. S. Mamede do Coronado, Portugal ; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto Porto, Portugal.
authors.forename: Patrício
authors.initials: P
authors.lastname: Soares-da-Silva
authors.affiliation: BIAL - Portela & Cª, S.A. S. Mamede do Coronado, Portugal.
authors.forename: Nuno
authors.initials: N
authors.lastname: Pires
authors.affiliation: BIAL - Portela & Cª, S.A. S. Mamede do Coronado, Portugal.
authors.forename: Maria João
authors.initials: MJ
authors.lastname: Bonifácio
authors.affiliation: BIAL - Portela & Cª, S.A. S. Mamede do Coronado, Portugal.
authors.forename: Ana I
authors.initials: AI
authors.lastname: Loureiro
authors.affiliation: BIAL - Portela & Cª, S.A. S. Mamede do Coronado, Portugal.
authors.forename: Nuno
authors.initials: N
authors.lastname: Palma
authors.affiliation: BIAL - Portela & Cª, S.A. S. Mamede do Coronado, Portugal.
authors.forename: Lyndon C
authors.initials: LC
authors.lastname: Wright
keywords: Carbamazepine; eslicarbazepine; fast inactivation; lacosamide; oxcarbazepine; slow inactivation; voltage-gated sodium channel